Literature DB >> 12796161

Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis.

Claudia Poleri1, José Luis Morero, Beatriz Nieva, María Fernanda Vázquez, Cristina Rodríguez, Ernesto de Titto, Moisés Rosenberg.   

Abstract

STUDY
OBJECTIVE: To evaluate the prognostic value of histopathologic variables and molecular markers in a group of patients with stage I non-small cell lung cancer (NSCLC).
SETTING: "María Ferrer" Hospital of Buenos Aires, Argentina. PATIENTS: Pathologic stage IA and IB patients who underwent radical surgery and nonneoadjuvant therapy for NSCLC between January 1985 and December 1999. MEASUREMENTS AND
RESULTS: Fifty-three patients fulfilling the inclusion criteria were identified. The overall survival was 52.8%, and 28% of patients had recurrent disease. We found significant differences between squamous cell carcinoma (SCC) and adenocarcinoma in mitotic counting (p = 0.001) and lymphatic permeation (p = 0.01). SCCs showed higher proliferation (MIB-1 grades 2 and 3) [p = 0.001], Bcl-2 expression (p = 0.038), and CD44 expression (p = 0.019) than adenocarcinomas. The log-rank test showed that mitosis count, necrosis, MIB-1, and Bcl-2 were predictive factors for relapse. All of them were associated with increased relapse and a shorter time to recurrence. Multivariate analysis using the Cox proportional hazards regression model showed that mitosis count, Bcl-2 expression, and grade 3 of MIB-1 emerged as independent prognostic factors of recurrence.
CONCLUSIONS: We found that mitosis count and MIB-1 expression had significant value to predict recurrence, reflecting the aggressiveness of high-rate proliferative tumors. We could also show that patients with positive Bcl-2 tumors had a poor outcome, probably related to the uncontrolled cell growth that the expression of Bcl-2 promotes. Our observations are of potential interest for the development of rational postresection treatment strategies based on the estimated risk of recurrence of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796161     DOI: 10.1378/chest.123.6.1858

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  What is better/reliable, mitosis counting or Ki67/MIB1 staining?

Authors:  Mark Kriegsmann; Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2016-10

3.  Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer.

Authors:  Cuicui Zhang; Yongsheng Jia; Yanan Jia; Xiaoling Zhang; Kai Li
Journal:  Int J Clin Oncol       Date:  2018-08-27       Impact factor: 3.402

4.  Prognostic value of the frequency of vascular invasion in stage I non-small cell lung cancer.

Authors:  Satoshi Okada; Shinjiro Mizuguchi; Nobuhiro Izumi; Hiroaki Komatsu; Michihito Toda; Kantaro Hara; Takahiro Okuno; Toshihiko Shibata; Hideki Wanibuchi; Noritoshi Nishiyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-10-13

5.  Differential expression of VASP in normal lung tissue and lung adenocarcinomas.

Authors:  L Dertsiz; G Ozbilim; Y Kayisli; G A Gokhan; A Demircan; U A Kayisli
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

6.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Christos Colovos; Camelia S Sima; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Mod Pathol       Date:  2011-10-07       Impact factor: 7.842

7.  Ki-67 expression in pulmonary tumors.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

8.  Prognostic implication of lymphatic vessel invasion in stage IB (pT2aN0M0) non-small cell lung cancer.

Authors:  Kunio Araki; Yoshin Adachi; Hiroyuki Metsugi; Takeshi Tokushima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-09-14

9.  High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors:  Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos
Journal:  BMC Cancer       Date:  2010-05-09       Impact factor: 4.430

10.  Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma.

Authors:  Kun-Hsing Yu; Gerald J Berry; Daniel L Rubin; Christopher Ré; Russ B Altman; Michael Snyder
Journal:  Cell Syst       Date:  2017-11-15       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.